UBICHEM Group adds new large scale manufacturing site in Hungary

12 June 2012

Independent UK company UBICHEM Group has announced further growth of its business by adding a new manufacturing site. The new member of the group, UBICHEM Pharma Manufacturing, will be producing starting materials, intermediates and other fine chemical products for pharma and non-pharma applications in industrial quantities. This expansion positions the UBICHEM Group to be one of the biggest providers in the Central and Eastern Europe (CEE) region.

The newly acquired 55,000m2 (590,000 square feet) facility is located in Budapest, Hungary, and it is able to produce fine chemical products in multi-ton quantities. The new manufacturing site also expands UBICHEM Group’s presence in the non-pharma sector. Financial terms were not disclosed.

”This new plant represents a milestone in UBICHEM history. From now on we are able to provide a comprehensive range of services from process R&D through pilot-scale cGMP API [active pharmaceutical ingredients] manufacture to high-volume manufacturing. By applying the rigorous quality control and strict production guidelines we have had in place at UBICHEM Pharma Services since 1996, we will now be able to ensure the high quality of the intermediates and fine chemical products at our new manufacturing site,” says chief executive Jozsef Repasi.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics